Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2019 - 2022)

SELLAS Life Sciences (SLS) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $16.1 million as the latest value for Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 185.72% to $16.1 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Dec 2022, up 185.72% year-over-year, with the annual reading at $16.1 million for FY2022, 185.72% up from the prior year.
  • Total Non-Current Liabilities for Q4 2022 was $16.1 million at SELLAS Life Sciences, up from $13.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $17.1 million in Q1 2022, with the low at $3.9 million in Q1 2020.
  • Average Total Non-Current Liabilities over 4 years is $8.5 million, with a median of $6.2 million recorded in 2019.
  • The sharpest move saw Total Non-Current Liabilities plummeted 58.14% in 2021, then surged 185.72% in 2022.
  • Over 4 years, Total Non-Current Liabilities stood at $5.6 million in 2019, then surged by 140.1% to $13.5 million in 2020, then tumbled by 58.14% to $5.6 million in 2021, then surged by 185.72% to $16.1 million in 2022.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $16.1 million, $13.2 million, and $13.0 million for Q4 2022, Q3 2022, and Q2 2022 respectively.